The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
The Combination of Oral All-trans Retinoic Acid and High-dose Dexamethasone vs High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia: A Multicenter, Randomized, Open-label Trial
Sponsor: Beijing Aerospace General Hospital
This PHASE2 trial investigates Immune Thrombocytopenia and is currently completed. Beijing Aerospace General Hospital leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Nov 2022 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2
-
Jul 2020 — Nov 2020 [monthly]
Recruiting PHASE2
-
Feb 2020 — Jul 2020 [monthly]
Recruiting PHASE2
First recorded
Jan 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Aerospace General Hospital
- Beijing Hospital
- Beijing Tongren Hospital
- Navy General Hospital, Beijing
- Peking University People's Hospital
- Qilu Hospital of Shandong University
For direct contact, visit the study record on ClinicalTrials.gov .